Puma Biotechnology finished first quarter 2019 with Non-GAAP adjusted net income of $8.1M
Puma Biotechnology finished first quarter 2019 with Non-GAAP adjusted net income of $8.1M
Pharmaceuticals, Biotechnology and Life Sciences
Puma Biotechnology finished first quarter 2019 with Non-GAAP adjusted net income of $8.1M
Ocular Therapeutix posts net loss of $17.1 million in the first quarter of 2019
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has launched a generic version of Tarceva®1(erlotinib) tablets, 100 and 150 mg, in the U.S.
Company management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from…
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued…
DUBLIN–(BUSINESS WIRE)–The “Parkinson’s Disease Drugs Market – Growth, Trends, and Forecast (2019-2024)” report has been added to ResearchAndMarkets.com’s offering. Parkinson’s…
STONY BROOK, N.Y.–(BUSINESS WIRE)–Applied DNA Sciences, Inc. (NASDAQ: APDN), will hold its 2019 Annual Meeting of Stockholders on Thursday, May…
– Study results across 17 medicines reflect our commitment to personalized care with advances in targeted therapies, immunotherapy, and diagnostics,…
GAITHERSBURG, Md.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CRO?src=hash" target="_blank"gt;#CROlt;/agt;–Smithers Avanza, a contract research organization (CRO) specializing in supporting development of large molecule therapeutics, announced…
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/DigitalDrugDesign?src=hash" target="_blank"gt;#DigitalDrugDesignlt;/agt;–Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical…